Reversal of Hypertriglyceridemia, Fatty Liver Disease, and Insulin Resistance by a Liver-Targeted Mitochondrial Uncoupler
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Summary Non-alcoholic fatty liver disease (NAFLD) affects one in three Americans and is a major predisposing condition for type 2 diabetes (T2D), however there are currently no drugs available to treat this disease. We examined whether a functionally liver-targeted derivative of 2,4-dinitrophenol (DNP), DNP-methyl ether (DNPME), could safely decrease hypertriglyceridemia, NAFLD and insulin resistance without systemic toxicities. Treatment with DNPME reversed hypertriglyceridemia, fatty liver and whole-body insulin resistance in high-fat fed rats and decreased hyperglycemia in a rat model of T2D with a wide therapeutic index. The reversal of liver and muscle insulin resistance was associated with reductions in tissue diacylglycerol content and reductions in PKCε and PKCθ activity in liver and muscle respectively. These results demonstrate that the beneficial effects of DNP on hypertriglyceridemia, fatty liver and insulin resistance can be dissociated from systemic toxicities and suggest the potential utility of liver-targeted mitochondrial uncoupling agents for the treatment of the related epidemics of NAFLD, metabolic syndrome and type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Self-citationMechanisms for Insulin Resistance: Common Threads and Missing Links
Samuel, V. T., & Shulman, G. I. (2012) · Cell · doi:10.1016/j.cell.2012.02.017 · Cited by 2,294 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) is a key factor in the pathogenesis of type 2 diabetes (T2D) and affects one in three Americans (Petersen et al., 2005; Samuel and Shulman, 2012).”
BackgroundSelf-citationYu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561 · cited 8×
“The COBAS Mira Plus (Roche Diagnostics) was used to measure plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood urea nitrogen (BUN), and creatinine was measured by LC-MS/MS. Daily creatinine clearance was measured by housing rats treated with DNPME or vehicle in metabolic cages for 24 hr…”
BackgroundMethodInfluentialSelf-citationMechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322 · cited 10×
“In this screen, we found that DNP-methyl ether (DNPME) both prevented and reversed nonalcoholic fatty liver disease, insulin resistance, and hyperglycemia in rat models of NAFLD and T2D without hepatic or renal toxicity.”
BackgroundMethodInfluentialSelf-citationGriffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D., Goodyear, L. J., Kraegen, E. W., White, M. F., & Shulman, G. I. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1270 · Cited by 1,267
Self-citationPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911 · cited 2×
“Nonalcoholic fatty liver disease (NAFLD) is a key factor in the pathogenesis of type 2 diabetes (T2D) and affects one in three Americans (Petersen et al., 2005; Samuel and Shulman, 2012).”
BackgroundSelf-citationWhite, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766 · cited 1×
“Furthermore, it is anticipated that NAFLDinduced NASH will soon surpass hepatitis C and alcoholic cirrhosis as the most common indication for liver transplantation in the US (White et al., 2012).”
BackgroundUCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals
Andrews, Z. B., Liu, Z.-W., Walllingford, N., Erion, D. M., Borok, E., Friedman, J. M., Tschöp, M. H., Shanabrough, M., Cline, G., Shulman, G. I., et al. (2008) · Nature · doi:10.1038/nature07181 · Cited by 710
Self-citation
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Self-citationDeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationThe pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
“However, a disassociation between ceramide content and tissue insulin resistance has been reported in multiple studies (70, 71, 81), and the underlying mechanism linking ceramides to insulin resistance has not been fully resolved.”
BackgroundInfluentialSelf-citationMitochondrial dysfunction: mechanisms and advances in therapy
Zong, Y., Li, H., Liao, P., Chen, L., Pan, Y., Zheng, Y., Zhang, C., Liu, D., Zheng, M., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01839-8 · Cited by 1,172
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
Perry, R. J., Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2014) · Nature · doi:10.1038/nature13478 · Cited by 1,136
Self-citationRegulation of hepatic glucose metabolism in health and disease
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,133
Self-citationEctopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease
Shulman, G. I. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1011035 · Cited by 1,126
Self-citationRyu, D., Mouchiroud, L., Andreux, P. A., Katsyuba, E., Moullan, N., Nicolet-dit-Félix, A. A., Williams, E. G., Jha, P., Lo Sasso, G., Huzard, D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4132 · Cited by 1,105
Mitochondrial and metabolic dysfunction in ageing and age-related diseases
Amorim, J. A., Coppotelli, G., Rolo, A. P., Palmeira, C. M., Ross, J. M., & Sinclair, D. A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00626-7 · Cited by 990
Mitochondria as a therapeutic target for common pathologies
Murphy, M. P., & Hartley, R. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.174 · Cited by 827
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
Self-citationPerry, R. J., Camporez, J.-P. G., Kursawe, R., Titchenell, P. M., Zhang, D., Perry, C. J., Jurczak, M. J., Abudukadier, A., Han, M. S., Zhang, X.-M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.012 · Cited by 719
“Liver ATP, ADP, AMP, NAD, and NADH concentrations were measured by LC-MS/MS as previously described (Perry et al., 2013).”
Self-citationTargeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678
Mitochondrial dysfunction and insulin resistance: an update
Montgomery, M. K., & Turner, N. (2015) · Endocrine Connections · doi:10.1530/ec-14-0092 · Cited by 527
Treatment of nonalcoholic fatty liver disease: role of AMPK
Smith, B. K., Marcinko, K., Desjardins, E. M., Lally, J. S., Ford, R. J., & Steinberg, G. R. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00225.2016 · Cited by 500
Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases
(2018) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.05.006 · Cited by 455
Metformin directly acts on mitochondria to alter cellular bioenergetics
Andrzejewski, S., Gravel, S.-P., Pollak, M., & St-Pierre, J. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-12 · Cited by 430
Roles of diacylglycerols and ceramides in hepatic insulin resistance
Petersen, M. C., & Shulman, G. I. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.004 · Cited by 373
Self-citationTargeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis
Chung, H. K., Ryu, D., Kim, K. S., Chang, J. Y., Kim, Y. K., Yi, H.-S., Kang, S. G., Choi, M. J., Lee, S. E., Jung, S.-B., et al. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201607110 · Cited by 357
Repairing mitochondrial dysfunction in disease
Sorrentino, V., Menzies, K. J., & Auwerx, J. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104908 · Cited by 337
Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo
Madiraju, A. K., Qiu, Y., Perry, R. J., Rahimi, Y., Zhang, X.-M., Zhang, D., Camporez, J.-P. G., Cline, G. W., Butrico, G. M., Kemp, B. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0125-4 · Cited by 297
Self-citationNiclosamide ethanolamine–induced mild mitochondrial uncoupling improves diabetic symptoms in mice
Tao, H., Zhang, Y., Zeng, X., Shulman, G. I., & Jin, S. (2014) · Nature Medicine · doi:10.1038/nm.3699 · Cited by 288
Self-citationControlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats
Perry, R. J., Zhang, D., Zhang, X.-M., Boyer, J. L., & Shulman, G. I. (2015) · Science · doi:10.1126/science.aaa0672 · Cited by 283
Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms
Steinberg, G. R., Valvano, C. M., De Nardo, W., & Watt, M. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.033 · Cited by 240
Finan, B., Clemmensen, C., Zhu, Z., Stemmer, K., Gauthier, K., Müller, L., De Angelis, M., Moreth, K., Neff, F., Perez-Tilve, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.014 · Cited by 191
Goldgof, M., Xiao, C., Chanturiya, T., Jou, W., Gavrilova, O., & Reitman, M. L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.568204 · Cited by 138
“A DNP prodrug (26) may also achieve some of its improved therapeutic index by reducing the peak concentration of the active species.”
BackgroundInfluentialScherer, P. E. (2016) · Diabetes · doi:10.2337/db16-0339 · Cited by 133
“That is a very powerful and a very effective way of dissipating excess energy, but we have to be very careful to have feedback mechanisms in place to avoid overheating (73,74).”
Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice
Alexopoulos, S. J., Chen, S.-Y., Brandon, A. E., Salamoun, J. M., Byrne, F. L., Garcia, C. J., Beretta, M., Olzomer, E. M., Shah, D. P., Philp, A. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16298-2 · Cited by 137
Geisler, J. G. (2019) · Cells · doi:10.3390/cells8030280 · Cited by 104
“Others have tested DNP in models of stroke, sciatic nerve injury, TBI, Aβ1-42 inhibition of plaque formation and various metabolic diseases [29,45,87,88,164,167,183].”
BackgroundBAM15‐mediated mitochondrial uncoupling protects against obesity and improves glycemic control
Axelrod, C. L., King, W. T., Davuluri, G., Noland, R. C., Hall, J., Hull, M., Dantas, W. S., Zunica, E. R., Alexopoulos, S. J., Hoehn, K. L., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012088 · Cited by 89
Lee, H.-Y., Lee, J. S., Alves, T., Ladiges, W., Rabinovitch, P. S., Jurczak, M. J., Choi, C. S., Shulman, G. I., & Samuel, V. T. (2017) · Diabetes · doi:10.2337/db16-1334 · Cited by 66
Self-citationLiu, D., Zhang, Y., Gharavi, R., Park, H. R., Lee, J., Siddiqui, S., Telljohann, R., Nassar, M. R., Cutler, R. G., Becker, K. G., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13176 · Cited by 68
“In a recent study (Perry et al., 2013), when DNP was administered to rats at the same dose (5 mg/kg) and by the same route (i.”
BackgroundInfluentialGoedeke, L., Peng, L., Montalvo-Romeral, V., Butrico, G. M., Dufour, S., Zhang, X.-M., Perry, R. J., Cline, G. W., Kievit, P., Chng, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aay0284 · Cited by 63
Self-citationGancheva, S., Kahl, S., Pesta, D., Mastrototaro, L., Dewidar, B., Strassburger, K., Sabah, E., Esposito, I., Weiß, J., Sarabhai, T., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1758 · Cited by 60
Self-citationZhang, Y., Shen, X., Xiao, X., Liu, M., Li, S., Yan, J., Jin, J., Gao, J., Zhen, C., Hu, N., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13578 · Cited by 55
Self-citationAntidiabetic and cardiovascular beneficial effects of a liver-localized mitochondrial uncoupler
Kanemoto, N., Okamoto, T., Tanabe, K., Shimada, T., Minoshima, H., Hidoh, Y., Aoyama, M., Ban, T., Kobayashi, Y., Ando, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09911-6 · Cited by 55
Targeting Alzheimer’s Disease: The Critical Crosstalk between the Liver and Brain
Huang, Z., Lin, H. W. (., Zhang, Q., & Zong, X. (2022) · Nutrients · doi:10.3390/nu14204298 · Cited by 50
Goedeke, L., Murt, K. N., Di Francesco, A., Camporez, J. P., Nasiri, A. R., Wang, Y., Zhang, X., Cline, G. W., de Cabo, R., & Shulman, G. I. (2022) · Aging Cell · doi:10.1111/acel.13539 · Cited by 22
Self-citationMaseko, T., Elkalaf, M., Peterová, E., Lotková, H., Staňková, P., Melek, J., Dušek, J., Žádníková, P., Čížková, D., Bezrouk, A., et al. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5342 · Cited by 21
Sustained-release mitochondrial protonophore reverses nonalcoholic fatty liver disease in rats
Wei, G., Song, X., Fu, Y., Gong, T., & Zhang, Q. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.072 · Cited by 19
Mitochondrial control of glycerolipid synthesis by a PEP shuttle
Yamamuro, T., Katoh, D., Silva, G. M., Nishida, H., Oikawa, S., Higuchi, Y., Wang, D., Fujimoto, M., Yoshida, N., Li, M., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.017 · Cited by 11
Metadata
- Authors
- Perry, R. J., Kim, T., Zhang, X.-M., Lee, H.-Y., Pesta, D., Popov, V. B., Zhang, D., Rahimi, Y., Jurczak, M. J., Cline, G. W., Spiegel, D. A., & Shulman, G. I.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 18
- Issue
- 5
- Pages
- 740-748
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2017004251
- Cited by
- 230
- References
- 12
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.